Compare FTAI Aviation Ltd (FTAI) vs Mesoblast Limited (MESO) Price & Performance

FTAI Aviation Ltd. (FTAI) trades at $169.13, down 3.26% over 24 hours, with a bearish technical signal from moving averages. Recent financials show strong revenue growth to $2.51B in 2025 and a net income margin of 15.94%, but earnings have missed expectations for three consecutive quarters. The company announced a $500 million share repurchase program and a strategic aircraft acquisition, signaling management confidence. Valuation ratios are elevated, with a P/E of 37.35 and P/B of 43.49, reflecting high growth expectations.

The outlook for FTAI is mixed; analyst consensus is unanimously bullish with a $321.25 price target, but near-term risks include earnings misses and negative operating cash flow. Long-term growth drivers include expansion in aerospace products and power segments, though execution risks and market volatility could pressure the stock. Investors should weigh strong institutional support against fundamental headwinds.

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.